Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Matza, K. Stewart, R. Paczkowski, K. Coyne, B. Currie, K. Boye (2018)
Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)Journal of Patient-Reported Outcomes, 2
Carl Baeyer (2009)
Children's self-report of pain intensity: what we know, where we are headed.Pain research & management, 14 1
K. Öberg, S. Lamberts (2016)
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.Endocrine-related cancer, 23 12
L. Saltz, B. Trochanowski, M. Buckley, Bernadette Heffernan, D. Niedzwiecki, Y. Tao, D. Kelsen (1993)
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumorsCancer, 72
M. Shah, W. Goldner, A. Benson, E. Bergsland, L. Blaszkowsky, P. Brock, J. Chan, Satya Das, P. Dickson, P. Fanta, T. Giordano, T. Halfdanarson, D. Halperin, Jin He, A. Heaney, M. Heslin, F. Kandeel, A. Kardan, S. Khan, B. Kuvshinoff, C. Lieu, Kimberly Miller, V. Pillarisetty, D. Reidy, S. Salgado, Shagufta Shaheen, H. Soares, M. Soulen, J. Strosberg, C. Sussman, N. Trikalinos, Nataliya Uboha, Namrata Vijayvergia, T. Wong, B. Lynn, Cindy Hochstetler (2021)
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 19 7
Satya Das, A. Dasari (2021)
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?Current Oncology Reports, 23
N. Pandya, Nancy Losben, J. Moore (2018)
Optimizing insulin delivery for patients with diabetesGeriatric Nursing, 39
S. Zafar, A. Abernethy (2013)
Financial toxicity, Part I: a new name for a growing problem.Oncology, 27 2
T. Haugland, M. Vatn, M. Veenstra, A. Wahl, G. Natvig (2009)
Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian populationQuality of Life Research, 18
J. Beaumont, D. Cella, A. Phan, Seung Choi, Zhimei Liu, James Yao (2012)
Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US PopulationPancreas, 41
M. Caplin, Mohid Khan, F. El-Khouly, P. Davies, C. Toumpanakis (2011)
Long‐term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 34
A. Dasari, Chan Shen, D. Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, T. Shih, James Yao (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 3
J. Strosberg, L. Kvols (2010)
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.World journal of gastroenterology, 16 24
A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold (2009)
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
Lei Qin, Stephanie Chen, E. Flood, A. Shaunik, B. Romero, M. Cruz, C. Alvarez, S. Grandy (2017)
Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United KingdomDiabetes Therapy, 8
S. Singh, D. Granberg, E. Wolin, R. Warner, M. Sissons, T. Kolarova, G. Goldstein, M. Pavel, K. Öberg, J. Leyden (2016)
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETsJournal of global oncology, 3
Feng Yang, C. Jin, D. Fu (2014)
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.The New England journal of medicine, 371 16
Daphne Adelman, A. Burgess, P. Davies (2012)
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative studyMedical Devices (Auckland, N.Z.), 5
A. Vinik, E. Wolin, H. Audry, E. Gomez-Panzani (2014)
ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs).Journal of Clinical Oncology, 32
P. Ryan, A. Phan, Daphne Adelman, M. Iwasaki (2016)
Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.Clinical journal of oncology nursing, 20 6
S. Dusetzina, H. Huskamp, N. Keating (2019)
Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.JAMA, 321 20
Daphne Adelman, Xuan-Mai Thanh, M. Feuilly, A. Houchard, D. Cella (2020)
Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)Advances in Therapy, 37
X. Pivot, Jean-Philippe Spano, M. Espié, P. Cottu, C. Jouannaud, V. Pottier, L. Moreau, J. Extra, Alain Lortholary, P. Rivera, Dominique Spaeth, H. Attar-rabia, Chahinez Benkanoun, L. Dima-Martinez, N. Esposito, J. Gligorov (2017)
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.European journal of cancer, 82
I. Tannock, C. Presley, L. Saltz (2019)
Value-Added Decisions in Oncology.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 39
M. Hjermstad, P. Fayers, D. Haugen, A. Caraceni, G. Hanks, J. Loge, R. Fainsinger, N. Aass, S. Kaasa (2011)
Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review.Journal of pain and symptom management, 41 6
PURPOSE:Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs). Lanreotide is more expensive and given by deep subcutaneous injection, whereas octLAR is given intramuscularly. We evaluated patient preference between these agents in terms of injection site pain.MATERIALS AND METHODS:Randomized, single-blinded study. Patients with NETs received injections every 4 weeks. Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order. Self-reported injection site pain scores (range, 0-10) were obtained after each of the first three injections. Primary end point was comparison of mean pain scores over the first three injections. Secondary end points included patient-reported preference.RESULTS:Fifty-one patients enrolled (26 in arm 1 and 25 arm 2), all evaluable for primary end point. No significant difference was identified in the mean pain score over the first three injections (2.4 ± 1.9 v 1.9 ± 1.5, P = .5). Thirty-four of 51 (67%) patients (15 in arm 1 and 19 in arm 2) completed post-therapy questionnaires and were evaluable for secondary end points. Seven patients (47%) in arm 1 and eight patients (42%) in arm 2 indicated no drug preference at the end of treatment. In the other 19 patients, more patients indicated mild or strong preference for octLAR over lanreotide.CONCLUSION:We found minimal pain with octLAR and lanreotide and no significant pain score differences between the two. Patients indicating a drug preference trended toward favoring octLAR.
JCO Oncology Practice – Wolters Kluwer Health
Published: Sep 20, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.